---
title: 'General Opportunity at Synolo Therapeutics'
canonical: 'https://feeny.ai/job/general-opportunity-synolo-therapeutics-cambridge-0g0h24xhwj0j'
type: 'job'
last_seen: '2026-09-10'
---

# General Opportunity at Synolo Therapeutics

- **Company:** Synolo Therapeutics
- **Location:** Cambridge, MA
- **Work type:** onsite
- **Posted:** 2026-02-10
- **Last confirmed live:** 2026-09-10
- **Apply:** https://jobs.lever.co/synolotx/fd2f06a9-a03c-4e86-955d-a0230a6dbd79

## Job description

About Synolo Therapeutics: Synolo Therapeutics, an early-stage biotechnology company launched by RA Ventures, is pioneering the development of precision-targeted immunotherapies for cancer. Powered by computational protein design and proprietary technologies that yield biological data sets at unprecedented scale and resolution, we are building a pipeline of first-in-class multi-specific biologics with novel functionalities. Synolo was founded by pioneers in the field of protein design and engineering, synthetic biology, DNA sequencing, immunology, and biologics drug discovery and development.

About RA Capital: RA Capital Management funds and builds healthcare and life science companies using an evidence-based investment approach informed by TechAtlas, a think tank within RA Capital which analyzes scientific and clinical data from academic literature and industry sources to anticipate how breakthroughs might impact industry stakeholders, physicians, patients, and policymakers. TechAtlas' analyses are captured in a unique collection of competitive landscapes, or ‘maps’, that identify competitive therapeutics, diagnostics, research tools, and/or technological capabilities in a given area.

At Synolo Therapeutics, we are committed to fostering a diverse and inclusive work environment where all individuals are valued and treated with dignity. We believe that diversity drives innovation and strengthens our ability to make a meaningful impact through our work. We are committed to being an equal opportunity employer who ensures that all qualified applicants receive equal consideration for employment without regard to neurodiversity, race/ethnicity, color, national origin, religion, gender, pregnancy, marital status, sexual orientation, gender identity/expression, age, disability, genetic information, military service, covered/protected veteran status or any other federal, state or local protected class.

We kindly ask that recruiting agencies and third-party recruiters do not contact us regarding this position. We are not seeking assistance or accepting unsolicited resumes from agencies at this time.

## About Synolo Therapeutics

## Company Overview
- **One-liner**: Synolo Therapeutics is developing logic-gated immunotherapies that activate only under specific biological conditions, aiming to treat both cancer and autoimmune diseases with higher safety and efficacy.
- **Entity Type**: Private (Pre-clinical / NewCo stage, launched by RA Ventures)
- **Headquarters**: Cambridge, Massachusetts, United States
- **Founded**: 2023
- **Founders**: Joshua Resnick (Co-Founder & Board Member), Kevin Grosselin (Scientific Co-Founder), Robert Nicol (Scientific Co-Founder)

## Core Business
- **Primary industry/industries**: Biotechnology, Immunotherapy, Oncology, Autoimmune Disease Therapeutics
- **Target customers**: B2B / Partnership (pharma and biotech partners); patients ultimately benefit from its therapeutics.
- **Mission or purpose statement**: Advancing a new class of precision-targeted immunotherapies that are conditionally active to be highly effective and safer than the current standard of care [synolotx.com](https://synolotx.com/).

## Products & Services
- **Logic-Gated Immunotherapy Platform**: A proprietary discovery platform based on computational protein design and high-scale biological data. It creates multi-specific biologics that are conditionally active, meaning they target only specific disease cells (cancer or autoimmune) while sparing healthy tissue. The platform is designed to be modular and applicable across multiple indications.

## Market Standing
- **Valuation/Market Cap**: Not publicly available (third-party estimate of ~$4.4 million by Prospeo, not a priced-round valuation) [whitefordresearch.com](http://biobase.whitefordresearch.com/companies/synolo-therapeutics).
- **Total Funding**: Undisclosed initial funding from RA Ventures / RA Capital Management (initial investment year: 2023) [racap.com](https://www.racap.com/portfolio/synolo-therapeutics).
- **Notable Investors/Partners**: RA Capital Management (via its venture division RA Ventures and the Raven Healthcare Incubator).
- **Growth Signals**: Headcount grew ~25% YoY to 18 employees, with 55% of staff in Research roles; monthly web traffic grew 86.2%; LinkedIn followers grew ~118% yearly [linkedin.com](https://linkedin.com/company/synolotherapeutics).

## Competitive Advantages
- **Conditional (logic-gated) selectivity**: Unlike conventional immunotherapies (e.g. many checkpoint inhibitors or CAR-T), Synolo's antibodies are designed to be "on" only in the specific microenvironment of a tumor or inflamed tissue, theoretically reducing systemic side effects.
- **Proprietary platform combining multiple fields**: Integrates computational protein design, synthetic biology, DNA sequencing, and immunology to create novel multi-specific biologics that are difficult to replicate.
- **Deep-pocketed, connected backer**: RA Capital Management is a highly respected healthcare-dedicated investment firm with a strong track record of creating and supporting biotech companies, providing significant strategic and financial stability.

## Strategic Focus
- **Build pipeline**: Rapidly advancing a portfolio of conditionally active immunotherapies from discovery toward the clinic, with a dual focus on cancer and autoimmune diseases.
- **Talent acquisition**: Heavily recruiting for senior scientific roles (Senior/Principal Scientist, Protein Science) and expanding the R&D team in Cambridge.
- **Platform validation**: Focusing on proving the modular platform's ability to generate leads across multiple targets and indications.

## Why Work Here
- **Innovative science at the frontier**: Work on a cutting-edge platform that combines computational protein design, synthetic biology, and immunology—rare to find at the startup level.
- **Strong backing and stability**: Backed by RA Capital, a firm that provides significant resources and a long-term view, unusual for an early-stage biotech.
- **On-site, collaborative culture**: Roles are based at the LabCentral 700 facility in Kendall Square, Cambridge—the heart of the biotech ecosystem. The company explicitly states that positions are on-site, fostering close collaboration between science and leadership.
- **High-growth, small team environment**: With 18 employees and clear plans to grow, you'd have outsized impact and exposure to leadership. The team includes former scientists from leading biotechs like Dragonfly Therapeutics, Capstan Therapeutics, and Aera Therapeutics.
- **Transparent hiring process**: The company informs candidates that AI tools may assist in reviewing applications, which suggests a modern, tech-enabled approach to recruitment [jobs.lever.co/synolotx](https://jobs.lever.co/synolotx).

## Sources
1. [synolotx.com](https://synolotx.com/)
2. [linkedin.com/company/synolotherapeutics](https://linkedin.com/company/synolotherapeutics)
3. [racap.com](https://www.racap.com/portfolio/synolo-therapeutics)
4. [jobs.lever.co/synolotx](https://jobs.lever.co/synolotx)
5. [whitefordresearch.com](http://biobase.whitefordresearch.com/companies/synolo-therapeutics)

## Other roles at Synolo Therapeutics

- [Senior Scientist/Principal Scientist, Protein Science](https://feeny.ai/job/senior-scientist-principal-scientist-protein-science-synolo-therapeutics-zc48y9pa7nfa) — Cambridge, MA
- [General Opportunity](https://feeny.ai/job/general-opportunity-monumental-no-location-yaxrhyrhnh42) — No Location
- [General Opportunity](https://feeny.ai/job/general-opportunity-voxel-remote-vpzwy9v9ghg4)
- [General Opportunity](https://feeny.ai/job/general-opportunity-harmonic-palo-alto-m52jhh18j8ps) — Palo Alto, CA
- [General Opportunity](https://feeny.ai/job/general-opportunity-vrchat-remote-kxkp4pz43an7)
- [General Opportunity](https://feeny.ai/job/general-opportunity-mytos-london-wb9h4jkeb87k) — London, United Kingdom
- [General Opportunity](https://feeny.ai/job/general-opportunity-fab2-austin-bzkyzvywz21e) — Austin, TX